Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity
Kirsten R Palmer, Tu'uhevaha J Kaitu'u-Lino, Roxanne Hastie, Natalie J Hannan, Louie Ye, Natalie Binder, Ping Cannon, Laura Tuohey, Terrance G Johns, Alexis Shub, Stephen Tong
HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
In preeclampsia, the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1) is released from placenta into the maternal circulation, causing endothelial dysfunction and organ injury. A recently described splice variant, sFLT-1 e15a, is primate specific and the most abundant placentally derived sFLT-1. Therefore, it may be the major sFLT-1 isoform contributing to the pathophysiology of preeclampsia. sFLT-1 e15a protein remains poorly characterized: its bioactivity has not been comprehensively examined, and serum levels in normal and preeclamptic pregnancy have not been reported. We generated and validated an sFLT-1 e15a-specific ELISA to further characterize serum levels during pre..View full abstract
Related Projects (5)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
This work was supported by The National Health and Medical Research Council (NHMRC; Project grant #1061977), The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Research Foundation Arthur Wilson scholarship (to K.R. Palmer), and The Keith Fitzmaurice Bursary (to K.R. Palmer). The following received salary support from NHMRC: S. Tong (#1050765), T.J. Kaitu'u-Lino (#1062418), N.J. Hannan (#628927), and K.R. Palmer (#607219).